* Forte Biosciences Inc reported a quarterly adjusted loss of $4.54​​ per share for the quarter ended September 30. The mean expectation of two analysts for the quarter was for a loss of $7.12 per share. Wall Street expected results to range from $-7.50 to $-6.75 per share.

* Reported revenue was zero​; analysts expected zero.

* Forte Biosciences Inc's reported EPS for the quarter was a loss of $4.54​.

* The company reported a quarterly loss of $8.39 million.

* Forte Biosciences Inc shares had fallen by 0.2% this quarter and lost 72.8% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts had fallen by about 25.7% in the last three months.​

* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Forte Biosciences Inc is 150.00 This summary was machine generated from LSEG data November 15 at 02:05 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Sep. 30 2024 -7.12 -4.54 Beat

Jun. 30 2024 -4.17 -6.75 Missed

Mar. 31 2024 -4.12 -4.00 Beat

Dec. 31 2023 -7.00 -4.65 Beat